Dr Horton Inc

D.R. Horton is the largest homebuilder in the United States by volume, consistently closing more homes annually than any competitor. Its strategy centers on the entry-level and first move-up buyer—segments where housing affordability pressures have concentrated the most pent-up demand. The company operates under multiple brands including value-focused Express Homes and luxury Emerald Homes, spans 33 states, and controls a financial services subsidiary for mortgages and a title company, capturing fee revenue across the full homebuying transaction.

D.R. Horton benefits from a persistent structural housing supply shortage that has accumulated over a decade, supporting demand even as mortgage rates climbed. Its scale gives it purchasing advantages over smaller builders. A healthy balance sheet and controlled lot pipeline differentiate it from more leveraged peers. The key risk is mortgage rate sensitivity—higher rates reduce affordability and can sharply suppress order volumes in a short window, making the business cyclically exposed to rate movements.

Lennar is the closest competitor by homes closed annually, followed by PulteGroup, which focuses more on move-up and active adult buyers. NVR operates a differentiated lot-option model that avoids land ownership risk entirely. KB Home and Taylor Morrison compete across overlapping geographic markets. Toll Brothers focuses on luxury buyers and is less of a direct rival to Horton's entry-level concentration.

D.R. Horton pays a regular quarterly dividend and has periodically issued special dividends during periods of exceptional cash generation. The ordinary dividend has grown over time alongside earnings, though the regular yield is modest relative to the stock price. Land acquisition and share repurchases compete with dividend growth as capital allocation priorities, reflecting management's view that reinvesting in growth often produces better long-term shareholder returns.

DHI last closed at $137.69, down 0.46% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $110.44 and a high of $184.55. The current price represents 37% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 26 analysts covering DHI, the consensus rating is Hold — 10 rate it a buy, 13 hold, and 3 sell. The average price target sits at $63.78, implying 54% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Dr Horton Inc generated $31.88B in revenue during fiscal year 2026, with $3.34B reaching the bottom line as net income. The net profit margin of 10.5% is solid for its sector.

DHI trades at a P/E ratio of 14.23 on trailing earnings of $11.01 per share. That's below the S&P 500 average, suggesting the market may see limited growth or is pricing in sector-specific risks. Comparing this multiple against Consumer products sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -5.90% (3M), -18.92% (6M), +6.42% (1Y), -5.51% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether DHI is outperforming or lagging the broader market.